GE Healthcare to Invest $50M to Boost Ultrasound Solution Adoption
GE Healthcare and Pulsenmore will also distribute products in Europe and collaborate closely to develop ultrasound-based healthcare offerings that cater to the homecare market.
Source: Getty Images
By - GE Healthcare will invest up to $50 million in start-up Pulsenmore to accelerate the global adoption of ultrasound solutions and pursue FDA clearance and commercial expansion.
The companies will also distribute Pulsenmore’s products in Europe and other markets as they become available and collaborate closely to develop ultrasound-based healthcare offerings that cater to the homecare market.
The complete offering includes a handheld ultrasound device that docks with the user’s smartphone, a mobile app for the patient to conduct consultation with a clinician, a web application for clinician-side interaction with the platform, and a software API enabling integration of Pulsenmore’s online services with organization health records.
The periodic fetal ultrasound scanning and consultation is offered as an online clinician-guided telecommunication service or as an offline application-guided service, a GE Healthcare spokesperson explained.
The homecare market is expected to reach $662.67 by 2027, and the telehealth market may expand at a compound annual growth rate (CAGR) of over 30% from 2022 to 2029.
Pulsenmore is well-positioned for the telehealth market with its novel self-operation prenatal home ultrasound solution. The solution combined with a smartphone enables pregnant women to self-scan for remote clinical assessment.
“Homecare opens the door to tremendous value for payers, healthcare facilities, physician groups and care-at-home providers, with the opportunity to improve patients’ quality of care and experience,” Roland Rott, CEO and president of GE Healthcare’s ultrasound, said in the announcement.
“We are excited about adding this highly complementary offering to our market leading Women’s Health and Primary Care standard of care ultrasound diagnostics solutions, marking a strong step forward in enabling precision health,” Rott continued.
In April 2021, GE Healthcare launched a point-of-care ultrasound (POCUS) system and an industry-first artificial intelligence (AI) offering in cardiac imaging on the Venue and Venue Go.
The Venue Fit offering is the smallest system in GE’s Venue family. The system features a touchscreen, scanning tools, and a small footprint designed to fit in tight spaces generally found in point-of-care settings.
GE’s AI ultrasound systems offer an industry-first AI tool for cardiac scanning with an integrated quality indicator and real-time entity framework (EF).
GE Healthcare will invest up to $50 million in start-up Pulsenmore to accelerate the global adoption of ultrasound solutions and pursue FDA clearance and commercial expansion.
The companies will also distribute Pulsenmore’s products in Europe and other markets as they become available and collaborate closely to develop ultrasound-based healthcare offerings that cater to the homecare market.
The complete offering includes a handheld ultrasound device that docks with the user’s smartphone, a mobile app for the patient to conduct consultation with a clinician, a web application for clinician-side interaction with the platform, and a software API enabling integration of Pulsenmore’s online services with organization health records.
The periodic fetal ultrasound scanning and consultation is offered as an online clinician-guided telecommunication service or as an offline application-guided service, a GE Healthcare spokesperson explained.
The homecare market is expected to reach $662.67 by 2027, and the telehealth market may expand at a compound annual growth rate (CAGR) of over 30% from 2022 to 2029.
Pulsenmore is well-positioned for the telehealth market with its novel self-operation prenatal home ultrasound solution. The solution combined with a smartphone enables pregnant women to self-scan for remote clinical assessment.
“Homecare opens the door to tremendous value for payers, healthcare facilities, physician groups and care-at-home providers, with the opportunity to improve patients’ quality of care and experience,” Roland Rott, CEO and president of GE Healthcare’s ultrasound, said in the announcement.
“We are excited about adding this highly complementary offering to our market leading Women’s Health and Primary Care standard of care ultrasound diagnostics solutions, marking a strong step forward in enabling precision health,” Rott continued.
In April 2021, GE Healthcare launched a point-of-care ultrasound (POCUS) system and an industry-first artificial intelligence (AI) offering in cardiac imaging on the Venue and Venue Go.
The Venue Fit offering is the smallest system in GE’s Venue family. The system features a touchscreen, scanning tools, and a small footprint designed to fit in tight spaces generally found in point-of-care settings.
GE’s AI ultrasound systems offer an industry-first AI tool for cardiac scanning with an integrated quality indicator and real-time entity framework (EF).
